Search+Investment IdeasBrokerages remain bullish on BEML, Titan and Fortis Healthcare, citing strong earnings. SynopsisBrokerages remain bullish on BEML, Titan and Fortis Healthcare, citing strong earnings, improving margins and growth prospects. Elara sees 58% upside in BEML, while Citi targets 5,700 for Titan and Nuvama sees 19% upside in Fortis Healthcare.Brokerages remain constructive on select Indian stocks, with BEML, Titan Company and Fortis Healthcare emerging as notable "Buy" calls backed by strong earnings momentum and improving growth prospects.Elara Capital sees nearly 58% upside in BEML, driven by strong Q1 sales, a sharp improvement in profitability and robust order inflows.Citi remains bullish on Titan, raising its target price to Rs 5,700 as jewellery growth stays resilient and BYETMarkets.com 5 mins readAug 10, 2026, 09:32:00 AM ISTGift this Story to your friendsFONT SIZEAbcSmallAbcMediumAbcLargeSAVEPRINTCOMMENTContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories & personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions & in-depth stock reportsSubscribe NowETUh-oh! This is an exclusive story available for selected readers only.Worry not. You’re just a step away.What’s Included withETPrime Membership
Buy, Sell or Hold: Elara Capital raises target price on BEML; Citi remains bullish on Titan Company
Brokerages remain bullish on BEML, Titan and Fortis Healthcare, citing strong earnings, improving margins and growth prospects. Elara sees 58% upside in BEML, while Citi targets 5,700 for Titan and Nuvama sees 19% upside in Fortis Healthcare.
Elara Capital sees 58% upside in BEML on Q1 growth and margins; Citi targets Rs 5,700 for Titan as jewellery demand stays strong. India consumption resilience supports enterprise GTM planning—though IT stack and infrastructure decisions remain independent of non-tech equity sentiment.






